Regeneron Pharmaceuticals News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

21.10.22	Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA® (aflibercept) Injection (PR Newswire)
14.10.22	Regeneron Pharma: CHMP Adopts Positive Opinion For Libtayo - Quick Facts (RTTNews)
14.10.22	Libtayo® (cemiplimab) Receives Positive CHMP Opinion Recommending Approval to Treat Advanced Cervical Cancer (PR Newswire)
12.10.22	Regeneron: EYLEA SBLA Gets FDA Priority Review - Quick Facts (RTTNews)
12.10.22	EYLEA® (aflibercept) Injection sBLA for Treatment of Retinopathy of Prematurity (ROP) Accepted for FDA Priority Review (PR Newswire)
11.10.22	Regeneron Reports Positive Results From Dupixent Phase 3 Trial In 1 To 11 Yrs With EoE (RTTNews)
11.10.22	Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old (PR Newswire)
04.10.22	Regeneron to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on November 3, 2022 (PR Newswire)
03.10.22	Regeneron Elects Dr. Craig B. Thompson to Board of Directors (PR Newswire)
30.09.22	Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO (PR Newswire)
29.09.22	Regeneron : FDA Approves Dupixent For Prurigo Nodularis Treatment (RTTNews)
28.09.22	Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis (PR Newswire)
16.09.22	Intellia: Interim Data Show NTLA-2001 Can Profoundly Reduce Serum TTR Levels (RTTNews)
16.09.22	Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis (PR Newswire)
16.09.22	Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet (PR Newswire)
15.09.22	Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers (PR Newswire)
12.09.22	Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma Presented at ESMO and Published in NEJM (PR Newswire)
12.09.22	Regeneron: Fianlimab With Libtayo Shows Greater Than 60% Response Rates In Phase 1 Trial (RTTNews)
12.09.22	Fianlimab (LAG-3 Inhibitor) Combined with Libtayo® (cemiplimab) Demonstrates Greater than 60% Response Rates in Two Independent Cohorts of Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 In... (PR Newswire)
10.09.22	Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors (PR Newswire)
09.09.22	Regeneron Announces Investor Call and Webcast at ESMO 2022 (PR Newswire)
08.09.22	Dupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis (PR Newswire)
08.09.22	Regeneron: Aflibercept 8 Mg Meets Primary Endpoints In Two Trials For DME And WAMD (RTTNews)
08.09.22	Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals (PR Newswire)
05.09.22	Late-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma (PR Newswire)
05.09.22	Sanofi: Dupixent Data Show Sustained Improvement For Up To 2 Yrs In 6-11 Years With Asthma (RTTNews)
05.09.22	ESMO Presentations of Libtayo® (cemiplimab), Fianlimab and Novel Bispecific Antibodies Showcase Expanding Potential of Regeneron's Oncology Pipeline in Multiple Cancers (PR Newswire)
29.08.22	Alnylam: Additional Data Shows Favorable Effects Of Cemdisiran On Different Measures Of proteinuria (RTTNews)
27.08.22	Biotech Stocks Facing FDA Decision In September (RTTNews)
25.08.22	Regeneron Announces Investor Conference Presentations (PR Newswire)
03.08.22	Regeneron Q2 Profit Down On Weak Revenues; Revises FY22 Margin, R&D Outlook (RTTNews)
03.08.22	Regeneron's REGN5678 Shows Encouraging Anti-tumor Activity When Combined With Libtayo (RTTNews)
03.08.22	Regeneron Reports Second Quarter 2022 Financial and Operating Results (PR Newswire)
03.08.22	Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (m... (PR Newswire)
27.07.22	Regeneron Genetics Center Discovers Rare Mutations In The CIDEB Gene That Protect Against Liver Disease (PR Newswire)
26.07.22	Regeneron Announces the 2022 Winners of the Regeneron Prize for Creative Innovation (PR Newswire)
14.07.22	Regeneron: Phase 3 Trial Of Dupixent In Children With Eosinophilic Esophagitis Meets Main Goal (RTTNews)
14.07.22	Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (PR Newswire)
12.07.22	Ultima Genomics signs development agreement with Regeneron aimed at driving the scale of genomic information for drug discovery and development (PR Newswire)
06.07.22	Regeneron to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2022 (PR Newswire)
01.07.22	Regeneron Completes Acquiring Sanofi's Stake In Libtayo (RTTNews)
01.07.22	Regeneron Completes Purchase of Sanofi's Stake in Libtayo® (cemiplimab) (PR Newswire)
29.06.22	Regeneron's EYLEA SBLA For 16-week Dosing Regimen In Diabetic Retinopathy Accepted For FDA Review (RTTNews)
29.06.22	EYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review (PR Newswire)
28.06.22	Biotech Stocks Facing FDA Decision In July 2022 (RTTNews)
24.06.22	NTLA : Study Of NTLA-2001 On Transthyretin Amyloidosis Shows Serum TTR Reductions Remained Durable (RTTNews)
24.06.22	Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions ... (PR Newswire)
09.06.22	Alnylam Pharma Reports Positive Topline Results From Phase 2 Study Of Cemdisiran (RTTNews)
08.06.22	Sanofi : FDA Approves Dupixent For Young Children With Moderate-to-severe Atopic Dermatitis (RTTNews)
07.06.22	FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

CieFinRichemont	137.35	1.40 %	K V
Sonova Hldg	297.30	1.29 %	K V
Logitech Intl	74.86	1.22 %	K V
Nestle	75.22	1.02 %	K V
Alcon	76.32	0.95 %	K V
UBS Group	28.17	-0.67 %	K V
Swiss Re	131.95	-0.68 %	K V
Geberit	533.80	-0.78 %	K V
Lonza Grp	541.40	-0.81 %	K V
Kuehne+Nagel Int	202.60	-1.65 %	K V

mehr

17.12.24		Schwacher Wochentag in New York: NASDAQ 100 verbucht letztendlich Abschläge
17.12.24		Minuszeichen in New York: NASDAQ 100 verliert nachmittags
17.12.24		Zurückhaltung in New York: NASDAQ 100 präsentiert sich schwächer
12.12.24		Schwache Performance in New York: NASDAQ 100 zeigt sich schlussendlich schwächer
12.12.24		Angespannte Stimmung in New York: NASDAQ 100 präsentiert sich schwächer
12.12.24		Schwacher Handel: NASDAQ 100 am Mittag in der Verlustzone
05.12.24		Börse New York in Rot: NASDAQ 100 zum Ende des Donnerstagshandels schwächer
19.11.24		Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen